Information Regarding New Testing that All Women Diagnosed with Breast Cancer Should Read
I haven’t posted here for a while because I have been incredibly busy holding workshops and doing individual health and nutrition counseling sessions. If you’ve been reading my blog posts you are well aware that I feel that diet and lifestyle changes are necessary to prevent breast cancer, and breast cancer recurrences–no matter what other treatments you should choose. Because of that I went back to school to study holistic nutrition, completed the publication of a nutrition/cookbook and started a new business called Empowered Health Resource. I have a sister web site www.empoweredhealthresource.com and a newsletter that I urge you to sign up for ( just shoot me an email and I’ll add you yo the newsletter list). As always–my mission is to empower you with knowledge so that you can make the best decisions regarding your health. From now on, I will only be posting here when information is specific ONLY to breast cancer, such as the information below.
NEW TEST WILL MAKE CHEMO MORE EFFECTIVE
If faced with the decision to undergo chemotherapy treatments, would you have chemotherapy if you knew it wouldn’t work? Of course not. Would you like to take a test to see if your cancer would be killed by the chemotherapy drugs before you make your decision? Of course you would. That test is available to all women with breast cancer, but the National Cancer Institute, the American Society of Clinical Oncology and the FDAis trying to stop you from knowing about it. Why? Because it will cut drug company profits on chemotherapy by nearly 50%.
This test is called a Tumor Chemosensitivity and Resistance Assay. This test will test your specific cancer cells ( no two cancers are identical) against the chemotherapy drugs prescribed by your oncologist to see if they will actually kill your cancer cells, and if not, other drugs will be tested on your cancer cells to determine which ones will kill them. Now doesn’t that sound like a smart thing to do? This test is done routinely in Europe.
Currently in the US, when chemotherapy is prescribed for breast cancer, it is not known wether it will work or not ( which is why it has a much lower rate of success here than it does in Europe). Chemotherapy drugs are prescribed based on the fact that in studies, they did work for a small percentage of women, but that they didn’t work at all for another percentage. In other words, it’s a crap shoot. But you can now demand ( and you will have to demand it–and probably pay for it yourself) a test to see if you will be in the percentage of women for whom the chemotherapy drugs will work.
Think of it this way—if diagnosed with breast cancer today, your breast cancer tumor is tested for hormone receptor status ( ER+, PR+, HER + ER-, PR-, HER -). That wasn’t always the case. About 10 years ago, if diagnosed with breast cancer, all women were put on Tamoxifen. But Tamoxifen didn’t work for a sizable percentage of women. So they started testing the cancer tumors against the drug Tamoxifen and discovered that it only worked for estrogen receptor positive breast cancers. Oncologists stopped prescribing it to women without ER+ breast cancer because it didn’t work for them and has terrible side effects. This same principle—-testing for effectiveness—it what the chemosensitivity assay is all about. If this test becomes standard, the results will be that some women will not get chemotherapy because they will not benefit from it, some women will be given a different– and effective– drug cocktail from the one initially prescribed by their oncologist, and those women that do receive chemo will know for sure that it will kill their cancer cells. All of those situations are positive for the patient. But the drug industry has already calculated that it will reduce their profits by 50%. And that is why you will have to demand this test. Beware—your oncologist has already been “schooled” by the drug companies in how to give you a false argument against having it.
For much more information on this test, including facts you need to know in order to stand your ground when demanding to have this test run, labs that can run the test and specifics on various cancers, read Customized Cancer Treatmentsby Ralph W. Moss, PhD.
New Drug for Triple Negative Breast Cancer
Recently in the news was fanfare over a new chemotherapy drug called Iniparib, that is suppose to be effective for triple negative breast cancer. Phase II clinical trials showed this drug to be effective in prolonging overall survival by 5 months (still not really effective by my definition). So the drug was rushed on to the next stage of clinical trials, the larger stage III trials. These trials did not show the same positive results. Could it be a case of deja vous? Just like with the drug Tamoxifen, maybe what’s needed here is some chemosensitivity testing to see why the drug worked for some women but not others—to determine what is different about their breast cancer cells.
I don’t know about you, but this constant concern over profit vs a real cure for breast cancer is getting quite old—and this newest twist in trying to deny this form of testing can only be stopped by women demanding to have the test performed!
